Shu-ting ZHANG,
Ming SHİ,
Lin-nan SHAO,
Shi-hang ZHOU,
Wei-jian YU,
Mei CHEN,
Nan XİAO,
Ying DUAN,
Ling-zi PAN,
Ni WANG,
Wen-qian SONG,
Yue-xin XİA,
Li ZHANG,
Ning Qİ,
Ming LİU
165166
Atypical Chemokine Receptor 1 Polymorphism can not Affect Susceptibility to Hepatitis C Virus
Atypical Chemokine Receptor 1 Polymorphism can not Affect Susceptibility to Hepatitis C Virus
Background: Hepatitis C virus has infected 130 to 150 million individuals globally. Atypical chemokine receptor 1 has become a focus of research because of its diverse roles in different diseases. However, little is known regarding the association of atypical chemokine receptor 1 polymorphism with susceptibility to hepatitis C virus. Aims: To determine the association of an atypical chemokine receptor 1 polymorphism (rs12075) with hepatitis C virus susceptibility. Study Design: Case-control study. Methods: We collected blood samples from 231 patients infected with hepatitis C virus and 239 blood donors as control subjects. Genotyping of atypical chemokine receptor 1 was performed using a 5ˊ-nuclease assay with TaqMan-minor groove binding probes. Comparisons between hepatitis C virus-infected patients and control subjects were assessed using Fisher’s exact test. Results: The genotype frequencies of FY*A/FY*A, FY*A/FY*B and FY*B/FY*B were 86.1%, 13.9% and 0% in the patient group, and 86.2%, 13.4% and 0.4% in the control group, respectively. The difference in atypical chemokine receptor 1 genotype frequencies between hepatitis C virus-infected patients and control group was not significant (p=1.00, OR=1.004, 95% CI=0.594-1.695). FY*A and FY*B allele frequencies were 93.1% and 6.9% in the patient group, and 92.9% and 7.1% in the control group, respectively. The difference in atypical chemokine receptor 1 allele frequencies between hepatitis C virus-infected patients and the control group was not significant (p=1.00, OR=0.972, 95% CI=0.589-1.603). Conclusion: Our result indicates that atypical chemokine receptor 1 polymorphism (rs12075) does not affect susceptibility to hepatitis C virus.
___
- 1. Williams R. Global challenges in liver disease. Hepatology 2006;44:521-6.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus
infection. Lancet Infect Dis 2005;5:558-67.
- 3. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic
hepatitis C virus infection. Nature 2005;436:946-52.
- 4. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global
epidemiology of hepatitis C virus infection: new estimates of age-specific
antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
- 5. Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, et al. A seroepidemiological
study on hepatitis C in China. Zhonghua Liu Xing Bing
Xue Za Zhi 2011;32:888-91.
- 6. Davis MB, Walens A, Hire R, Mumin K, Brown AM, Ford D, et al. Distinct
Transcript Isoforms of the Atypical Chemokine Receptor 1 (ACKR1) /
Duffy Antigen Receptor for Chemokines (DARC) Gene Are Expressed
in Lymphoblasts and Altered Isoform Levels Are Associated with Genetic
Ancestry and the Duffy-Null Allele. PloS one 2015;10:e0140098.
- 7. Grimberg BT, Udomsangpetch R, Xainli J, McHenry A, Panichakul T,
Sattabongkot J, et al. Plasmodium vivax invasion of human erythrocytes
inhibited by antibodies directed against the Duffy binding protein. PLoS
Med 2007;4:e337.
8-C, Racca L, Borras SG, Racca A. Duffy genotyping
facilitates transfusion therapy. Clin Exp Med 2009;9:249-51.
- 9. de Carvalho GB. Duffy Blood Group System and the malaria adaptation
process in humans. Rev Bras Hematol Hemoter 2011;33:55-64.
- 10. Iwamoto S, Li J, Sugimoto N, Okuda H, Kajii E. Characterization of
the Duffy gene promoter: evidence for tissue-specific abolishment of
expression in Fy(a-b-) of black individuals. Biochem Biophys Res
Commun 1996;222:852-9.
- 11. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW,
et al. The global distribution of the Duffy blood group. Nat Commun
2011;2:266.
- 12. Neote K, Mak JY, Kolakowski LF Jr, Schall TJ. Functional and biochemical
analysis of the cloned Duffy antigen: identity with the red blood cell
chemokine receptor. Blood 1994;84:44-52.
- 13. Darbonne WC, Rice GC, Mohler MA, Apple T, Hebert CA, Valente AJ, et
al. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J
Clin Invest 1991;88:1362-9.
- 14. King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg
LJ, et al. Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy
antigen affects susceptibility to Plasmodium vivax malaria. Proc Natl Acad
Sci USA 2011;108:20113-8.
- 15. Sippert EA, de Oliveira e Silva C, Visentainer JE, Sell AM. Association
of duffy blood group gene polymorphisms with IL8 gene in chronic
periodontitis. PloS one 2013;8:e83286.
- 16. Yang C, Yu KD, Xu WH, Chen AX, Fan L, Ou ZL, et al. Effect of genetic
variants in two chemokine decoy receptor genes, DARC and CCBP2, on
metastatic potential of breast cancer. PloS one 2013;8:e78901.
- 17. Kanto T, Hayashi N, Takehara T, Katayama K, Kato M, Akiyama M, et
al. Low expression of erythrocyte complement receptor type 1 in chronic
hepatitis C patients. J Med Virol 1996;50:126-34.
- 18. Miyaike J, Iwasaki Y, Takahashi A, Shimomura H, Taniguchi H, Koide N,
et al. Regulation of circulating immune complexes by complement receptor
type 1 on erythrocytes in chronic viral liver diseases. Gut 2002;51:591-6.
- 19. Ohi H, Tamano M, Okada N. Low CR1 (C3b receptor) level on erythrocytes
is associated with poor prognosis in hemodialysis patients. Nephron Clin
Pract 2008;108:23-7.
- 20. He W, Neil S, Kulkarni H, Wright E, Agan BK, Marconi VC, et al. Duffy
antigen receptor for chemokines mediates trans-infection of HIV-1 from
red blood cells to target cells and affects HIV-AIDS susceptibility. Cell
Host Microbe 2008;4:52-62.
- 21. Ramsuran V, Kulkarni H, He W, Mlisana K, Wright EJ, Werner L, et al.
Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility
in high-risk South African black women. Clin Infect Dis 2011;52:1248-56.
- 22. Cutbush M, Mollinson PL, Parkin DM. A new human blood group. Nature
1950;165:188-90.
- 23. Neote K, Darbonne W, Ogez J, Horuk R, Schall TJ. Identification of a
promiscuous inflammatory peptide receptor on the surface of red blood
cells. J Biol Chem 1993;268:12247-9.
- 24. Lettow I, Berres ML, Schmitz P, Müller T, Berg T, Neumann UP, et
al. A Duffy antigen receptor for chemokines (DARC) polymorphism
that determines pro-fibrotic chemokine serum concentrations is not
directly associated with severity of hepatitis C infection. Hum Immunol
2011;72:273-7.
- 25. Kashiwazaki M, Tanaka T, Kanda H, Ebisuno Y, Izawa D, Fukuma N, et
al. A high endothelial venule-expressing promiscuous chemokine receptor
DARC can bind inflammatory, but not lymphoid, chemokines and is
dispensable for lymphocyte homing under physiological conditions. Int
Immunol 2003;15:1219-27.
- 26. Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M,
et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis
progression after liver transplantation for hepatitis C infection. Hepatology
2011;53:596-603.
- 27. Palmer C, Corpuz T, Guirguis M, O'Toole S, Yan K, Bu Y, et al. The effect
of obesity on intrahepatic cytokine and chemokine expression in chronic
hepatitis C infection. Gut 2010;59:397-404.
- 28. Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of
hepatitis C infection. Hepatology 2009;49:676-88.
- 29. Comerford I, Milasta S, Morrow V, Milligan G, Nibbs R. The chemokine
receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur
J Immunol 2006;36:1904-16.
- 30. Schnabel RB, Baumert J, Barbalic M, Dupuis J, Ellinor PT, Durda P, et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2010;115:5289-99.